Valuation: Alterity Therapeutics Limited

Market Cap 41.09M 36.69M 33.9M 30.72M 57.47M 3.9B 58.42M 408M 161M 2.04B 154M 151M 6.44B P/E 2027 *
-2.49x
P/E 2028 * -0.23x
Enterprise Value 31.14M 27.8M 25.69M 23.28M 43.55M 2.96B 44.27M 309M 122M 1.55B 117M 114M 4.88B EV / Sales 2027 *
28.7x
EV / Sales 2028 * 2.13x
Free-Float
96.2%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Alterity Therapeutics Limited

1 day-1.96%
1 week-21.88%
Current month-37.89%
1 month-37.50%
3 months-55.75%
6 months-54.55%
Current year-37.50%
1 week 0.23
Extreme 0.23
0.3
1 month 0.23
Extreme 0.23
0.44
Current year 0.23
Extreme 0.23
0.78
1 year 0.23
Extreme 0.23
0.78
3 years 0.1
Extreme 0.1
0.95
5 years 0.1
Extreme 0.1
1.6
10 years 0.1
Extreme 0.1
20.5
Manager TitleAgeSince
Chief Executive Officer 65 2021-01-06
Director of Finance/CFO - 2024-09-29
Chief Tech/Sci/R&D Officer - 2019-03-31
Director TitleAgeSince
Director/Board Member 70 2005-07-28
Director/Board Member 47 2011-08-07
Director/Board Member 65 2025-11-20
Date Insider Type Main position Quantity % Market Cap. Importance
8/31/26 Exercice

Director

47,620 0.0216%
8/31/26 Buy

Chief Executive Officer

-47,620 0.0216%
8/31/26 Buy

Director

95,240 0.0432%
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%-21.88%-54.55%-28.57% 41.09M
+2.41%+0.29%+39.41%+73.38% 64.69B
-0.15%+7.50%+11.42%+75.22% 54.78B
+0.57%+4.60%+7.71%+100.57% 53.49B
+0.37%+4.67%+26.68%+54.16% 45.98B
-1.21%+2.32%+21.50%+126.83% 42.94B
-0.37%+5.07%+243.23%+834.48% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
+1.19%-4.98%+26.31%+0.33% 23.97B
-0.38%+5.68%+38.39%+29.86% 23.67B
Average +0.05%+0.40%+37.82%+131.48% 38.32B
Weighted average by Cap. +0.39%+2.73%+46.01%+151.29%

Financials

2027 *2028 *
Net sales 1.08M 968K 894K 810K 1.52M 103M 1.54M 10.76M 4.26M 53.9M 4.07M 3.98M 170M 1.95M 1.74M 1.61M 1.46M 2.73M 185M 2.78M 19.39M 7.68M 97.17M 7.33M 7.18M 306M
Net income -27.31M -24.39M -22.53M -20.42M -38.2M -2.59B -38.83M -271M -107M -1.36B -102M -100M -4.28B -30.69M -27.41M -25.32M -22.95M -42.93M -2.91B -43.64M -305M -121M -1.53B -115M -113M -4.81B
Net Debt -9.95M -8.89M -8.21M -7.44M -13.92M -945M -14.15M -98.81M -39.12M -495M -37.35M -36.56M -1.56B -36.93M -32.98M -30.47M -27.61M -51.66M -3.51B -52.51M -367M -145M -1.84B -139M -136M -5.79B
Projected Income Statement - Annual - Alterity Therapeutics Limited
Logo Alterity Therapeutics Limited
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The Company is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Employees
11
Date Price Change Volume
26-10-25 A$0.2500 -1.96% 2,090
26-10-23 A$0.2550 -3.77% 134,037
26-10-22 A$0.2650 +3.92% 395,725
26-10-21 A$0.2550 -5.56% 761,733
26-10-20 A$0.2700 -15.62% 606,640
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Alterity Therapeutics Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2550AUD
Average target price
5.517AUD
Spread / Average Target
+2,063.40%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alterity Therapeutics Limited